Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.
暂无分享,去创建一个
[1] J. Talwalkar,et al. The fate of indefinite and low‐grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation , 2013, Alimentary pharmacology & therapeutics.
[2] M. Neurath,et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis , 2013, Hepatology.
[3] Judy H. Cho,et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis , 2013, Nature Genetics.
[4] K. Lindor,et al. Inflammatory Bowel Disease in Primary Sclerosing Cholangitis: A Robust yet Changing Relationship , 2013, Inflammatory bowel diseases.
[5] K. Reddy,et al. Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[6] H. Said,et al. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. , 2013, The American journal of pathology.
[7] R. Chapman,et al. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. , 2013, Journal of hepatology.
[8] Y. Beyazit,et al. Circulating CD4+CD25+ Regulatory T Cells in the Pathobiology of Ulcerative Colitis and Concurrent Primary Sclerosing Cholangitis , 2013, Digestive Diseases and Sciences.
[9] C. Ponsioen,et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease , 2012, Inflammatory bowel diseases.
[10] M. Färkkilä,et al. Risk factors for complications of ERCP in primary sclerosing cholangitis , 2012, Endoscopy.
[11] G. Greenberg,et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.
[12] Y. Nakanuma,et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012 , 2012, Journal of hepato-biliary-pancreatic sciences.
[13] R. Poupon. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. , 2012, Clinics and research in hepatology and gastroenterology.
[14] P. Trivedi,et al. Review article: overlap syndromes and autoimmune liver disease , 2012, Alimentary pharmacology & therapeutics.
[15] K. Boberg,et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study , 2012, Scandinavian journal of gastroenterology.
[16] W. Sandborn,et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.
[17] D. Mould,et al. Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study , 2012, Inflammatory bowel diseases.
[18] G. Gores,et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. , 2012, Gastroenterology.
[19] A. Ganser,et al. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) , 2012, BMC Cancer.
[20] F. Remzi,et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] P. Dobrzanski,et al. The many faces of Janus kinase. , 2012, Biochemical pharmacology.
[22] M. Manns,et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders , 2012, Gut.
[23] K. Lindor,et al. Likelihood of Malignancy in Gallbladder Polyps and Outcomes Following Cholecystectomy in Primary Sclerosing Cholangitis , 2012, The American Journal of Gastroenterology.
[24] K. Boberg,et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients , 2012, Inflammatory bowel diseases.
[25] K. Boberg,et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia , 2012, Alimentary pharmacology & therapeutics.
[26] S. Vermeire,et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long‐term single‐centre study , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[27] T. Karlsen,et al. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. , 2012, World journal of gastroenterology.
[28] G. Gores,et al. Cancer surveillance in patients with primary sclerosing cholangitis , 2011, Hepatology.
[29] A. Bergquist,et al. Increased Risk of Colorectal Cancer and Dysplasia in Patients With Crohn's Colitis and Primary Sclerosing Cholangitis , 2011, Diseases of the colon and rectum.
[30] P. Neuhaus,et al. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[31] Jesse S. Voss,et al. Primary Sclerosing Cholangitis Patients With Serial Polysomy Fluorescence In Situ Hybridization Results Are at Increased Risk of Cholangiocarcinoma , 2011, The American Journal of Gastroenterology.
[32] K. Lindor,et al. High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis , 2011, Alimentary pharmacology & therapeutics.
[33] M. Pollheimer,et al. Will we ever model PSC? - "it's hard to be a PSC model!". , 2011, Clinics and research in hepatology and gastroenterology.
[34] A. Gill,et al. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures , 2011, British Journal of Cancer.
[35] A. Burroughs,et al. Meta‐analysis: ursodeoxycholic acid for primary sclerosing cholangitis , 2011, Alimentary pharmacology & therapeutics.
[36] T. Therneau,et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4‐associated cholangitis from cholangiocarcinoma , 2011, Hepatology.
[37] A. Alkhatib,et al. Comorbidities, Sphincterotomy, and Balloon Dilation Predict Post-ERCP Adverse Events in PSC Patients: Operator Experience Is Protective , 2011, Digestive Diseases and Sciences.
[38] S. Halpern,et al. Current Trends in Living Donor Liver Transplantation for Primary Sclerosing Cholangitis , 2011, Transplantation.
[39] K. Lindor. Farnesoid X receptor agonists for primary biliary cirrhosis , 2011, Current opinion in gastroenterology.
[40] E. Björnsson,et al. Primary Sclerosing Cholangitis Associated with Elevated ImmunoglobulinG4: Clinical Characteristics and Response to Therapy , 2011, American journal of therapeutics.
[41] J. O’Shea,et al. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.
[42] E. Björnsson,et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[43] E. Cholongitas,et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? , 2011, Gut.
[44] M. Manns,et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis , 2011, Hepatology.
[45] S. Schreiber,et al. Pregnancy in primary sclerosing cholangitis , 2011, Gut.
[46] J. Boyer,et al. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct–ligated rats and human hepatic cells , 2011, Hepatology.
[47] C. Weston,et al. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity , 2011, Hepatology.
[48] M. Manns,et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. , 2011, Journal of hepatology.
[49] M. Manns,et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. , 2010, Gastroenterology.
[50] D. Morris,et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis , 2010, Journal of Inflammation.
[51] M. Dave,et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. , 2010, Radiology.
[52] E. Björnsson,et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in sweden , 2010, Hepatology.
[53] R. Steele,et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) , 2010, Gut.
[54] C. Wijmenga,et al. Genome-wide association analysis in primary sclerosing cholangitis. , 2010, Gastroenterology.
[55] G. Gores,et al. Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.
[56] R. Odze,et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. , 2010, Gastroenterology.
[57] C. Lohse,et al. IgG4+ Plasma Cell Infiltrates in Liver Explants With Primary Sclerosing Cholangitis , 2010, The American journal of surgical pathology.
[58] O. Distler,et al. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies , 2009, Annals of the rheumatic diseases.
[59] T. Sauerbruch,et al. p-ANCAs in autoimmune liver disorders recognise human β-tubulin isotype 5 and cross-react with microbial protein FtsZ , 2009, Gut.
[60] O. Adeyi,et al. Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation , 2009, Journal of Clinical Pathology.
[61] S. Curbishley,et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. , 2009, Gastroenterology.
[62] M. Gershwin,et al. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis , 2009, Seminars in Immunopathology.
[63] R. Odze,et al. Pathologic Features of Ulcerative Colitis in Patients With Primary Sclerosing Cholangitis: A Case-control Study , 2009, The American journal of surgical pathology.
[64] C. Bowlus,et al. The immunobiology of primary sclerosing cholangitis , 2009, Seminars in Immunopathology.
[65] Thomas Korn,et al. IL-17 and Th17 Cells. , 2009, Annual review of immunology.
[66] U. Spengler,et al. Atypical p-ANCA in PSC and AIH: A Hint Toward a “leaky gut”? , 2009, Clinical reviews in allergy & immunology.
[67] Natalie J Torok,et al. Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study , 2009, The American Journal of Gastroenterology.
[68] D. Rockey. Current and future anti-fibrotic therapies for chronic liver disease. , 2008, Clinics in liver disease.
[69] E. Cholongitas,et al. Pathogenesis of primary sclerosing cholangitis. , 2008, Journal of hepatology.
[70] Y. Nakanuma,et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease , 2008, Proceedings of the National Academy of Sciences.
[71] B. Portmann,et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long‐term outcome and survival , 2008, Alimentary pharmacology & therapeutics.
[72] R. Chapman,et al. Etiopathogenesis of primary sclerosing cholangitis. , 2008, World journal of gastroenterology.
[73] D. Hommes,et al. A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis , 2008, Journal of clinical gastroenterology.
[74] K. Boberg,et al. The natural history of small-duct primary sclerosing cholangitis. , 2008, Gastroenterology.
[75] A. Bergquist,et al. Gallbladder disease in patients with primary sclerosing cholangitis. , 2008, Journal of hepatology.
[76] B. Petersen,et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. , 2008, Gastroenterology.
[77] M. Haider,et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging , 2008, Hepatology.
[78] N. LaRusso,et al. Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[79] E. Björnsson,et al. Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature , 2007, Hepatology.
[80] G. Kaplan,et al. The Burden of Large and Small Duct Primary Sclerosing Cholangitis in Adults and Children: A Population-Based Analysis , 2007, The American Journal of Gastroenterology.
[81] C. Verslype,et al. Incidence, Diagnosis, and Therapy of Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis , 2007, Digestive Diseases and Sciences.
[82] A. Bergquist,et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. , 2007, Gastroenterology.
[83] A. Befeler,et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2007, Current gastroenterology reports.
[84] M. Trauner,et al. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. , 2007, Seminars in liver disease.
[85] C. Paulusma,et al. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein) , 2007, Pflügers Archiv - European Journal of Physiology.
[86] B. Sharma,et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non‐alcoholic steatohepatitis , 2006, Journal of gastroenterology and hepatology.
[87] T. Smyrk,et al. Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis , 2006, The American Journal of Gastroenterology.
[88] J. Kleibeuker,et al. Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for Recurrence and De Novo Disease , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[89] J. Hasday,et al. Invited review: Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease , 2006, Journal of endotoxin research.
[90] M. Ziol,et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC , 2006, Hepatology.
[91] S. Radley,et al. Adenocarcinoma in an Ileoanal Pouch Formed for Ulcerative Colitis in a Patient With Primary Sclerosing Cholangitis and a Liver Transplant: Report of a Case and Review of the Literature , 2006, Diseases of the colon and rectum.
[92] K. Zatloukal,et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. , 2006, The American journal of pathology.
[93] K. Zatloukal,et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2006, Gastroenterology.
[94] W. Stremmel,et al. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis , 2006, European journal of gastroenterology & hepatology.
[95] K. Boberg,et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.
[96] L. Rybicki,et al. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis , 2005, Alimentary pharmacology & therapeutics.
[97] M. Vieth,et al. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment , 2005, Gut.
[98] G. Gores,et al. The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis , 2005, Digestive Diseases and Sciences.
[99] Tsutomu Masaki,et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[100] R. Chapman,et al. Review article: current management of primary sclerosing cholangitis , 2005, Alimentary pharmacology & therapeutics.
[101] A. Bergquist,et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. , 2005, Journal of hepatology.
[102] A. Zinsmeister,et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis , 2004, Gut.
[103] M. Färkkilä,et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo‐controlled trial , 2004, Hepatology.
[104] T. Therneau,et al. A Comparison of Routine Cytology and Fluorescence in situ Hybridization for the Detection of Malignant Bile Duct Strictures , 2004, The American Journal of Gastroenterology.
[105] H. Tilg,et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2004, Gastroenterology.
[106] B. Petersen,et al. Cost‐minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis , 2004, Hepatology.
[107] E. Kaltenthaler,et al. A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography. , 2004, Health Technology Assessment.
[108] S. Wigmore,et al. ROUX-EN-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis , 2004, Transplantation.
[109] T. Therneau,et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. , 2003, Gastroenterology.
[110] P. Marotta,et al. Liver transplantation for primary sclerosing cholangitis. , 2003, Transplantation proceedings.
[111] L. Tsui,et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis , 2003, Human Genetics.
[112] K. Lindor,et al. Is there a role for liver biopsy in primary sclerosing cholangitis? , 2003, American Journal of Gastroenterology.
[113] R. Chapman. The management of primary sclerosing cholangitis , 2003, Clinics in liver disease.
[114] K. Boberg,et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis , 2002, Gut.
[115] D. Jewell,et al. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study , 2002, Gut.
[116] J. Reitsma,et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population , 2002, Gut.
[117] T. Ang,et al. Clinical profile of primary sclerosing cholangitis in Singapore , 2002, Journal of gastroenterology and hepatology.
[118] S. Sumitran-Holgersson,et al. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6 , 2002, Gut.
[119] P. Heidenreich,et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. , 2002, Gastrointestinal endoscopy.
[120] K. Lindor,et al. Small‐duct primary sclerosing cholangitis: A long‐term follow‐up study , 2002, Hepatology.
[121] G. Gores,et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant , 2002, American Journal of Gastroenterology.
[122] A. Bergquist,et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. , 2002, Journal of hepatology.
[123] P. Sauer,et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. , 2002, Journal of hepatology.
[124] D. Adams,et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease , 2002, The Lancet.
[125] K. Boberg,et al. Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation , 2002, Scandinavian journal of gastroenterology.
[126] R. Chapman,et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. , 2001, Gastroenterology.
[127] D. Adams,et al. MAdCAM‐1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM‐1 in chronic inflammatory liver disease) , 2001, Hepatology.
[128] T. Karlsen,et al. Primary sclerosing cholangitis , 2001, The Lancet.
[129] W. Kremers,et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.
[130] M. Kimmey,et al. Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis , 2001, Annals of Internal Medicine.
[131] K. Lindor,et al. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. , 2000, Journal of hepatology.
[132] N. LaRusso,et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.
[133] C. Benz,et al. [Primary sclerosing cholangitis]. , 2000, Der Internist.
[134] B. Petersen,et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.
[135] N. LaRusso,et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.
[136] K. Lindor,et al. Serum autoantibodies in patients with primary sclerosing cholangitis. , 2000, Journal of hepatology.
[137] R. N. Macsween,et al. Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. , 1999, Liver.
[138] G. Gores,et al. Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis , 1999, Hepatology.
[139] I. Durieu,et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. , 1999, Journal of hepatology.
[140] K. Boberg,et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. , 1999, Tissue antigens.
[141] K. Batts,et al. Recurrence of primary sclerosing cholangitis following liver transplantation , 1999, Hepatology.
[142] J. Ebbesen,et al. [Incidence and prevalence of autoimmune liver diseases]. , 1998, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[143] P. Scheuer,et al. Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. , 1998, Mayo Clinic proceedings.
[144] P. Scheuer. Pathologic Features and Evolution of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis , 1998 .
[145] K. Lindor. Ursodiol for Primary Sclerosing Cholangitis , 1997 .
[146] T. Therneau,et al. A revised natural history model for primary sclerosing cholangitis. , 1997, Mayo Clinic proceedings.
[147] Å. Danielsson,et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. , 1996, Gut.
[148] N. LaRusso,et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. , 1996, Gut.
[149] L. Eriksson,et al. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential , 1995, Hepatology.
[150] Å. Danielsson,et al. Colchicine treatment of primary sclerosing cholangitis. , 1995, Gastroenterology.
[151] R. Hultcrantz,et al. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. , 1995, Gastroenterology.
[152] S. Yamada,et al. Small duct cholangitis induced byn-formyll-methioninel-leucinel-tyrosine in rats , 1994, Journal of Gastroenterology.
[153] S. Jalkanen,et al. Induction and function of vascular adhesion protein-1 at sites of inflammation , 1993, The Journal of experimental medicine.
[154] R. Vaughan,et al. Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis , 1992 .
[155] H. Waldum. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. , 1992, Journal of hepatology.
[156] R. Sartor,et al. Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats , 1991, Immunologic research.
[157] A. Zinsmeister,et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. , 1990, Gastroenterology.
[158] R. Wiesner,et al. Gallbladder disease in patients with primary sclerosing cholangitis. , 1988, AJR. American journal of roentgenology.
[159] R. Wiesner,et al. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. , 1986, Gastroenterology.
[160] R. Wiesner,et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. , 1983, Radiology.
[161] C. Holdsworth,et al. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. , 1980, Gut.
[162] R. Chapman,et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. , 1980, Gut.
[163] G. Kaplan,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Incidence of Primary Sclerosing Cholangitis: a Systematic Review and Meta-Analysis , 2011 .
[164] K. Lindor,et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[165] Christian Gieger,et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci , 2011, Nature Genetics.
[166] K. Lindor,et al. What's Hot in the Red Journal This Month , 2011, The American Journal of Gastroenterology.
[167] G. Gores,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Long-Term Outcomes of Positive Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis , 2009 .
[168] K. Zatloukal,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Side Chain Structure Determines Unique Physiologic and Therapeutic Properties of norUrsodeoxycholic Acid in Mdr2 / Mice , 2009 .
[169] F. Lammert,et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.
[170] J. Hasday,et al. Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. , 2006 .
[171] M. Kaplan,et al. A Pilot Study of Etanercept in the Treatment of Primary Sclerosing Cholangitis , 2004, Digestive Diseases and Sciences.
[172] K. Itoh,et al. Autoimmune pancreatitis and multiple bile duct strictures treated effectively with steroid , 2003, Journal of Gastroenterology.
[173] K. Lindor. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. , 1997, The New England journal of medicine.
[174] J. Rodés,et al. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. , 1994, Journal of hepatology.
[175] R. Chapman,et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. , 1994, Gastroenterology.
[176] A. Parés,et al. Epidemiology of primary sclerosing cholangitis in Spain , 1994 .
[177] R. Vaughan,et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. , 1992, Hepatology.